18F-GP1

**[18F]-GP1 is a fluorine-18 labeled small-molecule radiotracer developed for positron emission tomography (PET) imaging of thrombi. It is a derivative of the GPIIb/IIIa antagonist elarofiban and binds with high affinity (IC50 = 20 nM) to the GPIIb/IIIa receptor on activated platelets, which plays a key role in platelet aggregation and thrombus formation. The tracer enables sensitive detection of arterial and venous thrombi, as well as embolic events, by targeting activated platelets within clots. [18F]-GP1 demonstrates rapid blood clearance, low background signal, high clot-to-blood ratio, and favorable radiation dosimetry comparable to other clinical PET tracers. It was originally developed by Bayer HealthCare Pharmaceuticals and further advanced by Life Molecular Imaging in collaboration with the University of Zurich for diagnostic imaging applications in acute thromboembolism such as deep vein thrombosis, pulmonary embolism, and arterial thromboembolism.[1][2][3][4][6][7]**

Other names

[18F]GP1